Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten

Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM). 1 Olivotto I. Oreziak A. Barriales-Villa R. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020; 396: 759-769 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten. 1 Olivotto I. Oreziak A. Barriales-Villa R. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020; 396: 759-769 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar ,2 Desai M.Y. Owens A. Geske J.B. et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. Journal of the American College of Cardiology. 2022; 80: 95-108 Crossref PubMed Scopus (0) Google Scholar However, the effect of mavacamten on the frequency and management of new/recurrent AF episodes in oHCM receiving mavacamten following its Food and Drug Administration (FDA) approval remains only partially explored. 3 Rader F. Oręziak A. Choudhury L. et al. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC:Heart Failure. 2024; 12: 164-177 Crossref Scopus (3) Google Scholar As such, we sought to ascertain the impact of mavacamten on the phenotype of newly detected and recurrent AF in a tertiary cohort of oHCM receiving mavacamten post-FDA approval.